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Hypercalcemia is defined as a serum calcium concentration that is greater than 2 standard 
deviations above the normal mean, which in children may vary with age and sex, reflecting 
changes in the normal physiology at each developmental stage. Hypercalcemic disorders in 
children may present with hypotonia, poor feeding, vomiting, constipation, abdominal pain, 
lethargy, polyuria, dehydration, failure to thrive and seizures. In severe cases renal failure, 
pancreatitis and reduced consciousness may also occur and older children and adolescents 
may present with psychiatric symptoms. The causes of hypercalcemia in children can be 
classified as parathyroid hormone (PTH)-dependent or PTH-independent, and may be 
congenital or acquired. PTH-independent hypercalcemia, i.e. hypercalcemia associated with a 
suppressed PTH, is commoner in children than PTH-dependent hypercalcemia. Acquired 
causes of PTH-independent hypercalcemia in children include hypervitaminosis; 
granulomatous disorders and endocrinopathies. Congenital syndromes associated with PTH-
independent hypercalcemia include idiopathic infantile hypercalcemia (IIH); William’s 
syndrome; and inborn errors of metabolism. PTH-dependent hypercalcemia is usually caused 
by parathyroid tumors, which may give rise to primary hyperparathyroidism (PHPT) or 
tertiary hyperparathyroidism, which usually arises in association with chronic renal failure 
and in the treatment of hypophosphatemic rickets. Acquired causes of PTH-dependent 
hypercalcemia in neonates include maternal hypocalcemia and extra-corporeal membrane 
oxygenation. PHPT usually occurs as an isolated non-syndromic and non-hereditary 
endocrinopathy, but may also occur as a hereditary hypercalcemic disorder such as familial 
hypocalciuric hypercalcemia, neonatal severe primary hyperparathyroidism, and familial 
isolated primary hyperparathyroidism, and less commonly, as part of inherited complex 
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syndromic disorders such as multiple endocrine neoplasia (MEN). Advances in identifying 
the genetic causes have resulted in increased understanding of the underlying biological 
pathways and improvements in diagnosis. The management of symptomatic hypercalcemia 
includes interventions such as fluids, anti-resorptive medications and parathyroid surgery. 
This article presents a clinical, biochemical and genetic approach to investigating the causes 





Hypercalcemia in children is less common than in adults, but it nevertheless is more likely to 
be of clinical significance (1). The differential diagnosis of hypercalcemia in children (Table 
1) and adults is similar, but there are marked differences in the frequencies with which they 
occur. Thus, congenital causes are more frequent in children than acquired causes, such as 
malignancy, which are more common in adults (Table 1) (1). The causes of the 
hypercalcemia also depend on the age of the child, with congenital anomalies being more 
common in neonates, and with adolescents being affected by conditions typically seen in 
adults. Establishing the causes of hypercalcemia in a child may be challenging and this article 





DEFINITION AND PRESENTATION OF HYPERCALCEMIA 
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Hypercalcemia is defined as a serum calcium concentration that is greater than 2 standard 
deviations above the normal mean, and this in adults is usually an ionised calcium above 
~1.32 mmol/L (normal range 1.16-1.32 mmol/L) (Table 2), and a total serum calcium, which 
comprises 55%-60% ionised calcium plus 40%-45% protein bound (mainly to albumin) 
calcium, of ~2.60 mmol/L (normal range 2.20-2.60 mmol/L, 8.5-10.5 mg/dl). It is important 
to distinguish true hypercalcemia from an increased total calcium level secondary to an 
increase in protein binding, as the two conditions may also overlap. For example 
hypercalcemia can cause severe dehydration that in turn may result in hyperalbuminemia, 
resulting in a concurrent increase in calcium binding. The total calcium adjusted for albumin 
is calculated by the formulae: adjusted calcium = total calcium - albumin + 4.0, where 
calcium is in mg/100 ml and albumin in g/100 ml (2); or adjusted calcium = total calcium + 
({40-albumin}x 0.02), where calcium is in mmol/L and albumin in g/L (equivalent to 0.02 
mmol/L calcium for every 1g/L albumin 40g/L). Moreover, ionised and total serum calcium 
concentrations may vary with age and sex, reflecting changes in the normal physiology at 
each developmental stage and reference ranges have been established for the different age 
groups (Table 2). Generally, ionised and total serum calcium concentrations are higher in 
preterm and full-term neonates, where ionised calcium is above the 95% reference limits for 
adults from about the third day until at least 2 weeks post-partum (3). 
 
The presentation of hypercalcemia in children may range from an incidental asymptomatic 
biochemical finding to symptoms of hypotonia, poor feeding, vomiting, constipation, 
abdominal pain, lethargy, failure to thrive, polyuria, dehydration and seizures (4, 5) . In 
severe cases, renal failure, pancreatitis and reduced consciousness may also occur, and older 
children and adolescents may present with psychiatric symptoms (6). Clinical history and 
examination may provide diagnostic clues and guide further investigations. The presence or 
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absence of symptoms of hypercalcemia may indicate a particular diagnosis, and the urgency 
with which investigations should be pursued. For example, mild non-progressive 
asymptomatic hypercalcemia may potentially indicate a diagnosis of familial hypocalciuric 
hypercalcemia (FHH), whereas, severe hypercalcemia associated with fractures and 
respiratory distress is suggestive of the life-threatening disorder of neonatal severe primary 
hyperparathyroidism (NSHPT) (7). In addition, a dietary assessment, details of existing 
medical problems and medications (including over-the-counter supplements), and a family 
history may help to reveal the cause of the hypercalcemia. Physical examination should 
include an assessment for dysmorphic features, which may reveal a genetic syndrome, and 
for sequelae of hypercalcemia, such as bony deformities. Finally, the clinical details of the 
parents should be assessed as the neonate’s condition will have been influenced by the in 
utero environment. In addition, it is important to measure the serum calcium concentrations 
of the parents, because a hypercalcemic neonate may have inherited FHH from the mother, or 
be at a high risk of developing transient NSHPT if inheritance of FHH, due to an inactivating 
calcium sensing receptor (CaSR) mutation, is from the father and the mother is 
normocalcemic (8). 
 
CLASSIFICATION OF HYPERCALCEMIA AND PATHOPHYSIOLOGY 
 
There is no formal classification or grading system for defining the severity of 
hypercalcemia. However, the severity of clinical symptoms are more likely to be associated 
with greater elevations in plasma calcium concentrations, and hypercalcemia is generally 
considered to be mild, moderate and severe for total serum calcium concentrations <12mg/dL 
(3.00 mmol/L), between 12 and 14 mg/dL (3.00 to 3.50 mmol/L), and >14mg/dL (3.50 
mmol/L), respectively (9). A classification of hypercalcemia that is useful in identifying the 
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underlying etiologies can also be based on an understanding of the pathophysiological 
mechanisms. Thus, hypercalcemia may arise through increased bone resorption (e.g. from 
lytic bone lesions), increased gastrointestinal absorption of calcium (e.g. through enhanced 
1,25(OH)2D3 production), and decreased renal excretion of calcium (e.g. through the action 
of thiazides) (Figure 1). Hypercalcemia may result from more than one mechanism; for 
example excessive PTH causes increased gut absorption of calcium through enhanced 
1,25(OH)2D3 production, and also stimulates calcium resorption in bone and renal tubules. 
The causes of hypercalcemia may also be classified by whether the circulating PTH 
concentrations are elevated, i.e. hypercalcemia that is PTH-dependent (e.g. as occurring in 
parathyroid tumors), or reduced, i.e. hypercalcemia that is PTH-independent (e.g. through 
excessive production of PTHrP by a cancer, or an excess production of downstream 
mediators such as 1,25(OH)2D3) (Table 1 and Figure 2). Primary hyperparathyroidism 
(PHPT) and malignancy, which account for >90% of hypercalcemia in adults (10) , are rare 
in children and likely account for <5% of hypercalcemia in children, in whom other causes, 
especially those that are PTH-independent and due to genetic abnormalities, are more likely 
(Table 1). A careful history (e.g. for vitamin D ingestion, drugs, renal disease) and 
examination (e.g. for dysmorphology, endocrinopathies, granulomatous diseases), together 









PTH-independent hypercalcemia, which is commoner in children than PTH-dependent 
hypercalcemia, may be due to many and diverse causes which may be genetic or acquired 
(Table 1) and include hypervitaminosis D and A; drugs; malignancies; granulomatous 
disorders; endocrinopathies; renal tubular disorders; chronic inflammatory disorders; 
infections; immobilisation; congenital syndromes; and inborn errors of metabolism. These 
disorders, some of which may be associated with either high plasma concentrations of 
25(OH)D3 or  1,25(OH)2D3 concentrations, will be reviewed (Figure 2). 
 
HYPERCALCEMIA ASSOCIATED WITH HIGH PLASMA 25(OH)D3 
CONCENTRATIONS 
 
Hypercalcemia following vitamin D intoxication may occur due to incorrect prescriptions or 
accidental overdosing (11-14). For example, in the summer of 2016, >70 children were 
reported to develop hypercalcemia after receiving a vitamin D preparation that contained 75 
times higher levels than those recommended (15, 16). Hypercalcemia may also complicate 
the use of single high dose vitamin D therapy (600,000 i.u. vitamin D3, also known as Stoss 
(from the German “to shove”) therapy), that is utilised by some centres for the treatment of 
vitamin D insufficiency or deficiency in children with rickets or cystic fibrosis (17-20). The 
precise mechanism by which high doses of 25(OH)D3 can cause hypercalcemia remains 
unclear. In normal physiology, 25(OH)D3 binds to the vitamin D receptor (VDR) with very 
low affinity in contrast to its active metabolite, 1,25(OH)2D3. In 25(OH)D3 toxicity, 
25(OH)D3 precursors and metabolites are elevated but 1,25(OH)2D3 is usually normal, 
thereby suggesting that the hypercalcemia is not due to the actions of 1,25(OH)2D3. It has 
been proposed that the high concentrations of circulating 25(OH)D3 displace 1,25(OH)2D3  
from the vitamin D binding protein, thereby increasing the free concentrations of 
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1,25(OH)2D3 which then stimulate gene transcription via the VDR (21). It is important to 
note that excessive exposure to sunlight does not pose a risk of vitamin D toxicity, because 
the UVB light stimulates production and destruction of vitamin D3. Thus, 7-
dehydroxyxholesterol is converted to previtamin D3 under UVB, and previtamin D3 is then 
converted to vitamin D3 at the plasma membrane; however, UVB light also degrades 
previtamin D3 and vitamin D3, thereby allowing an equilibrium to be reached and thereby 
preventing excessive vitamin D3 production (22). 
 
HYPERCALCEMIA ASSOCIATED WITH HIGH PLASMA 1,25(OH)2D3  
CONCENTRATIONS 
 
High circulating 1,25(OH)2D3  concentrations may arise because of excessive renal synthesis 
associated with phosphate depletion, extra-renal activation of the 1α-hydroxylase enzyme 
with overproduction of 1,25(OH)2D3, or because of impaired renal catabolism of 
1,25(OH)2D3 to its inactive metabolite 1,24,25(OH)3D3 (Figure 1). 
 
Increased renal synthesis of 1,25(OH)2D3 in association with phosphate depletion 
Vitamin D metabolism is affected by phosphate homeostasis and the actions of the phosphate 
hormone fibroblast growth factor (FGF23) which are to inhibit and stimulate the activities of 
the renal 1α-hydroxylase (CYP27B1) and 1,25-dihydroxyvitamin D-24-hydroxylase 
(CYP24A1), respectively (Figure 1). Renal phosphate reabsorption in the proximal tubule 
involves the sodium-phosphate cotransporters 2A (NaPi-IIa) and 2C (NaPi-IIc), and 
phosphate reabsorption by NaPi-IIa is controlled by FGF23 and PTH (23). Loss of phosphate 
transport activity due to defects of NaPi-IIa, encoded by the solute carrier 34A1 gene 
(SLC34A1), results in phosphate depletion with a decrease in circulating FGF23 
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concentrations, that releases the inhibition of the 1α-hydroxylase and causes inappropriate 
excessive production of 1,25(OH)2D3 (23), which leads to hypercalcemia, hypercalciuria and 
nephrocalcinosis, a combination of features seen in children with idiopathic infantile 
hypercalcemia (IIH). IIH classically presents in the first year of life with failure to thrive, 
vomiting, dehydration and lethargy, and may be fatal. The hypercalcemia usually resolves by 
1 year of age, but in some individuals it may persist into adulthood (24). In addition, some 
patients may later develop hypercalciuria and be at risk of developing renal stone disease and 
osteoporosis, such that long-term surveillance is recommended for these patients (25). IIH is 
an autosomal recessive disorder, and two types of IIH (IIH1 and IIH2) are recognised, and 
are due to homozygous, or compound heterozygous mutations of the CYP24A1 and 
SLC34A1 genes (26)(23)(27).  
 
Extra-renal synthesis of 1,25(OH)2D3 in malignant  and granulomatous diseases 
Lymphomas and ovarian dysgerminomas can be extra-renal sites of 1α-hydroxylase activity, 
and hypercalcemia due to elevated production of 1,25(OH)2D3 may occur in 15% and 5% of 
patients with non-Hodgkins and Hodgkins lymphoma, respectively (28, 29). Similarily, 
macrophages represent an extra-renal site that can have substantial 1α-hydroxylase activity. 
Sequestration of macrophages in granulomatous and inflammatory tissues (e.g. sarcoidosis, 
tuberculosis, HIV immune reconstitution syndrome, leprosy, fungal granuloma including 
coccidiomycosis, cat scratch fever, Crohn’s disease, CMV, histoplasmosis and subcutaneous 
fat necrosis of the newborn) can cause dysregulated production of 1,25(OH)2D3 leading to 
hypercalcemia (30-36). Subcutaneous fat necrosis of the newborn (SFN) is an unusual form 
of lobular panniculitis that typically affects newborns born at term or post-term, often with a 
preceding history of birth trauma or birth asphyxia, and may occur from birth up until the 
first 6 weeks of life. SFN may also be associated with hypothermia or therapeutic cooling, 
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and It is characterised by single or multiple erythematous violaceous plaques and nodules that 
can evolve into calcifications and tend to occur on the back, face, buttocks and shoulders (31, 
32). It is associated with hypercalcemia that can be life threatening and the severity and 
duration of hypercalcemia are associated with the extent of the skin lesions (31). It has been 
proposed that an insult on the immature fat cells, such as exposure to cold (e.g. therapeutic 
hypothermia for hypoxia-ischemia encephalopathy or hypoperfusion) (31), may result in the 
development of necrosis and the development of a granulomatous infiltrate in the necrotic 
areas. In keeping with this, abundant levels of 1α-hydroxylase have been found in affected 
tissues, which may lead to increased production of 1,25(OH)2D3 with associated 
hypercalcemia as reported in other granulomatous disorders (37).  
 
Impaired degradation of 1,25(OH)2D3 
Loss-of-function mutations of 1,25-dihydroxyvitamin D2 24-hydroxylase, encoded by 
cytochrome P450 family 24 subfamily A member 1 (CYP24A1), resulting in impaired 
catabolism of 25(OH)D3 and 1,25(OH)2D3 to their inactive metabolites 1,24,25(OH)3D3 and 
24,25(OH)2D3, may be associated with elevated circulating levels of the active metabolites 
and the disorder IIH (25, 38).  
 
 
HYPERCALCEMIA NOT ASSOCIATED WITH ALTERED VITAMIN D 
CONCENTRATIONS 
 
PTH-independent hypercalcemia may arise without alterations in circulating 25(OH)D3 or 
1,25(OH)2D3 concentrations, and the causes for this form of hypercalcemia include: 
malignancies that may produce parathyroid hormone-related peptide (PTHrP); drugs and 
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vitamins; endocrinopathies; renal tubular disorders; congenital and hereditary syndromes and 
skeletal diseases; inborn errors of metabolism; and specific neonatal disorders.  
 
Drugs and vitamin A toxicity  
Drugs such as thiazides and vitamin A (retinol), vitamin A derivatives (e.g. its active 
metabolite, retinoic acid), and inappropriate doses of calcium carbonate and sodium 
bicarbonate to patients with chronic renal failure resulting in milk alkali syndrome can cause 
hypercalcemia (39-44). Thus, thiazides act to increase renal calcium reabsorption, which may 
cause hypercalcemia or unmask hypercalcemia from other causes that had been compensated 
for by hypercalciuria (40, 43, 44). Isotretinoin (13-cis-retinoic acid), which is used for 
treatment of severe acne and neuroblastoma, may also cause hypercalcemia by increasing 
osteoclastic bone resorption (41, 45). However, vitamin A toxicity is a rare cause of 
hypercalcemia and may occur in children with malabsorptive conditions such as cystic 
fibrosis (39) given supplements containing preformed vitamin A of which 70-90% is 
absorbed, thereby making children particularly sensitive to overdose. It is important to note 
that vitamin A toxicity does not occur with high intake of provitamin carotenoids from fruit 
and vegetables as conversion to the active form of vitamin A is required, and this rarely 
occurs when large quantities of foods such as fish or animal liver that contain a bioavailable 
form (retinol) are ingested.  
 
Malignancy and PTHrP 
Cancers associated with hypercalcemia in children include hematological malignancies (e.g. 
leukemias, lymphomas, and myeloma), neurological tumors including neuroblastoma, 
rhabdomyosarcoma, hepatic tumors (e.g. hepatoblastoma and hepatocellular carcinoma), and 
dysgerminomas (46-50). Hypercalcemia is associated with malignancy in <1% of children 
 12 
(4), and may be caused by: osteolysis due to metastases or leukemias; or osteoclastic bone 
resorption stimulated by hormones (e.g. PTHrP) that are produced by the tumor. PTHrP acts 
as a paracrine and intracrine hormone to regulate bone development, but some tumors (e.g. 
renal cell carcinomas, squamous cell carcinomas, dysgerminomas, ovarian and breast 
carcinomas, pheochromocytoma (51, 52), benign congenital mesoblastic nephroma (53)), 
multicystic dysplastic kidney disease (54) and renal dysplasia (55, 56)) may secrete PTHrP 
systemically, and the actions of circulating PTHrP on the type 1 PTH/PTHrP receptor cause 





Endocrine disorders, such as pheochromocytoma, Addison’s disease, thyrotoxicosis and 
severe congenital hypothyroidism may be associated with development of hypercalcemia in 
children. The hypercalcemia associated with pheochromocytoma may be due to secretion of 
PTHrP (51, 52). In Addison’s disease the hypercalcemia may be due to increased intestinal 
calcium absorption (57), that is possibly aggravated by volume depletion due to lack of 
mineralocorticoid hormone. Thyroid hormone in children increases bone resorption and 
skeletal growth; however, in thyrotoxicosis there is also premature fusion of growth plates, 
resulting in short stature (57), which leads to a negative balance between bone formation and 
resorption (58) and this may possibly explain the development of hypercalcemia. Severe 
congenital hypothyroidism in neonates may be associated with mild hypercalcemia in <40% 
of children (59), although it is rarely symptomatic and the mechanisms remain unknown. 
Moreover, levothyroxine treatment in children with congenital hypothyroidism (59) may also 
lead to an increase in circulating levels of 1,25(OH)2D3 and hypercalciuria, and 
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hypercalcemia has been reported to only occur in neonates with congenital hypothyroidism 
who were treated with levothyroxine and vitamin D supplementation, although the 
hypercalcemia was not correlated with circulating vitamin D concentrations or metabolites of 
vitamin D (60).  
 
Renal tubular disorders 
Distal renal tubular acidosis has been reported to be associated with hypercalcemia (61). In 
addition, Bartter syndrome type 1 (neonatal), which is characterized by metabolic alkalosis, 
renal hypokalemia and secondary hyperaldosteronism (62), and is due to mutations in the 
sodium-potassium-chloride co-transporter-2 gene (SLC12A1), has also been reported to be 
associated with hypercalcemia, hypercalciuria and nephrocalcinosis (62-64). However, the 
hypercalcemia was associated with increased circulating PTH concentrations, which may be 
explained by an inappropriate response to hypocalcemia secondary to hypercalciuria (63) and 
is consistent with marginally increased circulating PTH concentrations that have been 
reported in other, older children with Bartter syndrome (64).  
 
Inborn errors of metabolism 
Inborn errors of metabolism that are reported to be associated with hypercalcemia include 
hypophosphatasia (HPP), congenital lactase deficiency (CLD), disaccharide intolerance and 
blue diaper syndrome. HPP is characterised by reduced bone mineralization due to loss-of-
function mutations in tissue-nonspecific alkaline phosphatase (TNSALP), encoded by the 
Alkaline Phosphatase Liver/Bone/Kidney (ALPL) gene. HPP is classified into 6 forms, and 
each is characterised by age of onset and severity of symptoms, ranging from severe perinatal 
(lethal), where respiratory distress from a hypoplastic chest is the main cause of death, to 
milder odontohypophosphatasia, where only dental manifestations are seen (65).  Patients 
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present perinatally or in childhood and >30% may have hypercalcemia (66). The 
hypercalcemia is seen in the infantile form of HPP, and may resolve spontaneously within the 
first year of life (67), or following targeted asfotase alfa enzyme replacement therapy (68). 
However, hypercalcemia may occur in adults with HPP who have been immobilized (69). In 
CLD, the severely reduced or absent activity of the gut enzyme lactase, leads to an inability 
to breakdown dietary lactose, which results in osmotic diarrhoea, dehydration and weight loss 
shortly after feeding commences, and patients typically have hypercalcemia with 
nephrocalcinosis. CLD, an autosomal recessive disorder (70-73), is caused by a mutation of 
the lactase-phlorizin hydrolase gene, with a reported incidence of 1:60,000 newborns in 
Finland (73), although it can occur in other populations (70-73). Hypercalcemia in CLD 
usually resolves within weeks after starting a lactose-free diet, whereas nephrocalcinosis may 
persist for years (74). The hypercalcemia in CLD may be secondary to, or exacerbated by, 
dehydration and a metabolic acidosis, or be by a direct action of lactose on the gut (74). 
Hypercalcemia and nephrocalcinosis may also complicate the presentation of sucrose-
isomaltase deficiency (75), and it is thought that there may be a similar underlying 
mechanism  to CLD. Blue diaper syndrome is due to an abnormality of tryptophan 
metabolism that results in diarrhoea in association with excessive urinary excretion of indole 
derivatives (76). The characteristic “blue diaper” is caused by the high levels of indecan 
formed when high levels of unabsorbed tryptophan in the intestine are metabolised by 
bacteria (76). The mechanisms causing hypercalcemia in blue diaper syndrome, which is 
associated with hypercalciuria and nephrocalcinosis, are not known. Hypercalcemia in the 
absence of renal dysfunction may also be a rare complication of primary oxalosis (77) and 
has also been reported in IMAGe Syndrome (characterized by Intrauterine growth restriction, 




Immobilisation hypercalcemia may occur in 10-23% of children with spinal cord injuries, in 
association with suppressed plasma PTH concentrations, within 4-8 weeks of the injury (79), 
and be preceded by hypercalciuria, which may develop within the first week and continue for 
up to 18 months (79). Immobilisation hypercalcemia also occurs in some children after single 
limb fractures (80). The hypercalcemia is more common in adolescents and males, possibly 
because of increased bone turnover associated with rapid growth, and a higher bone mass, 
respectively (79). The mechanism is not understood but is thought to result from increased 
osteoclastic activity and reduced osteoblastic activity due to a lack of mechanical stimulation 
(79).  
 
Congenital syndromes and diseases 
Hypercalcemia is more likely to be genetic in children than in adults, and may occur as part 
of congenital syndromes that are associated with dysmorphism and/or skeletal abnormalities. 
These disorders, which include Williams syndrome, Jansen’s disease and Down syndrome 
are often detected early in life. However, in some cases dysmorphia may be subtle or missed, 
and therefore the diagnoses should not necessarily be ruled out on the basis of age alone. 
 
Williams syndrome 
Williams syndrome affects approximately 1 in 7,500-10,000 individuals (81) and is 
characterised by elfin-like facies, learning disabilities, supravalvular aortic stenosis, 
nephrocalcinosis, urinary tract abnormalities, and endocrinopathies including hypercalcemia, 
which affects 5 to 50% of patients (81-83). It usually occurs sporadically, but may be 
inherited in an autosomal dominant manner (84). The mechanisms causing hypercalcemia, 
which may resolve spontaneously within days to weeks (83), remain unknown, but abnormal 
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1,25(OH)2D3 metabolism and decreased calcitonin production have been implicated (81, 83, 
85), although no abnormality has been consistently demonstrated. Hemizygosity due to a 
microdeletion of chromosome 7q11.23 involving the ELASTIN and LIM-KINASE genes, 
which may explain the respective cardiovascular and neurologic features, have been reported 
in Williams syndrome. However, the calcitonin receptor gene, located on chromosome 7q21 
and close to the region deleted in Williams syndrome, was not involved in the deletion in four 
patients, indicating that it is unlikely to be implicated in the hypercalcemia of such children. 
Another, as yet uncharacterised gene that is within this contiguously deleted region is likely 
to be involved to explain the abnormalities of calcium metabolism.    
 
Jansen’s Disease 
Jansen’s metaphyseal chondroplasia is an autosomal dominant disease characterised by short 
limbed dwarfism in association with severe hypercalcemia and hypercalciuria, despite normal 
or undetectable PTH and PTHrP concentrations. These abnormalities are associated with 
heterozygous mutations of the PTH-PTHrP receptor, causing constitutive ligand independent 
activation (86).  
 
Down syndrome 
Down syndrome, which is due to trisomy 21, is one of the most frequent genetic causes of 
dysmorphism, and occurs in 1 in 690 live births (87). Down syndrome has been reported in 
association with hypercalcemia and nephrocalcinosis in 6 patients (88). The mechanisms 
causing the hypercalcemia are unknown, although the hypercalcemia does appear to respond 




Acquired causes of neonatal hypercalcemia 
 
Nutritional 
Enriched formula and/or phosphate depletion can cause hypercalcemia in preterm newborns 
(89) and, less frequently, in newborns born at term (90). Phosphate depletion may suppress 
secretion of FGF-23, alleviating the inhibitory effect of FGF-23 on 1,25(OH)2D3 production 
(Figure 1), causing an increase in 1,25(OH)2D3 levels resulting in hypercalcemia. The data on 
plasma PTH concentrations from such babies is scant and it has been suggested that as the 
hypercalcemia is associated with hypophosphatemia and increased plasma 1,25(OH)2D3  
concentrations, then the plasma PTH is likely to be low (90). The hypercalcemia in these very 
low birth weight babies fed breast milk, which has a relatively high calcium to phosphate 




PTH-dependent hypercalcemia is usually caused by parathyroid tumors, which may give rise 
to PHPT or tertiary hyperparathyroidism (Table 1 and Figure 2). PHPT usually occurs as an 
isolated non-syndromic non-hereditary endocrinopathy and less commonly, as part of 
inherited complex syndromic disorders such as multiple endocrine neoplasia (MEN) and 
hyperparathyroid jaw-tumor syndrome (HPT-JT) (91). Tertiary hyperparathyroidism usually 
arises in association with chronic renal failure, and may also occur in the treatment of 
children with hypophosphatemic rickets (92).  
The main non-parathyroid tumor related cause of PTH-dependent hypercalcemia in 
children is gestational maternal hypocalcemia (Table 1). This acquired cause of 
hypercalcemia may be apparent from the clinical history and preliminary investigations, 
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whereas the causes associated with parathyroid tumors, which include genetic abnormalities 
may be more challenging, and will be reviewed further. 
 
GENETIC CAUSES OF HYPERCALCEMIA 
 
PHPT may occur as a hereditary familial disorder or sporadically, i.e. as non-familial disease 
(93-95); however, distinguishing between sporadic and non-familial forms may sometimes be 
difficult. Sporadic PHPT may be the result of a de novo germline mutation in the patient or 
due to an inherited mutation with an absent family history, for example if family members 
have not been investigated or have died before developing symptoms (91). Both de novo and 
inherited mutations resulting in PHPT will lead to an increased risk of hereditary PHPT in the 
children of the patient (93-96). Studies of patients with both syndromic and non-syndromic 
forms of PHPT have shown that >10% will harbor a germline mutation in one of 12 genes 
(Table 3) (55, 93, 94, 97, 98). The non-syndromic forms, which include familial 
hypocalciuric hypercalcemia (FHH), neonatal severe primary hyperparathyroidism (NSHPT), 
and familial isolated primary hyperparathyroidism (FIHP), are likely to be more frequent than 




Multiple Endocrine Neoplasia (MEN) 
Multiple Endocrine Neoplasia (MEN) is an autosomal dominant disorder in which patients 
develop 2 or more endocrine tumors. Four types of MEN (MEN1-4) are recognised with each 
associated with a distinct set of endocrine tumors; however, parathyroid tumors occur in all 
of the MEN syndromes. Thus, in MEN1 patients, parathyroid tumors occur in 95% of 
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patients in association with pancreatic islet cell tumors (~40% of patients), anterior pituitary 
tumors (~30% of patients) and adrenocortical tumors (~40% of patients) (96). In MEN1, 
parathyroid tumors causing hypercalcemia are the first manifestation of the disease in 90% of 
patients, and parathyroid tumors may develop as early as 8 years of age, although only 17% 
of cases below 21 years of age will be symptomatic with urolithiasis, fatigue and bone pain, 
with the youngest symptomatic case being aged 8 years with urolithiasis (99). In MEN1, 
hyperparathyroidism is typically a multigland disease affecting all 4 parathyroid glands and 
patients who undergo subtotal parathyroidectomy usually develop recurrent hypercalcemia 
within a decade (100, 101). In MEN2, parathyroid tumors occur in ~20% of patients, in 
association with medullary thyroid carcinoma (MTC) (~99% of patients) and 
pheochromocytomas (~50% of patients) (96, 101). In MEN3, MTC and pheochromocytomas 
are also common, but parathyroid tumors are rarely seen; instead patients have other features 
such as a Marfanoid habitus, mucosal neuromas, medullated corneal nerve fibres and 
intestinal autonomic ganglion dysfunction leading to multiple diverticula and megacolon. 
Only a few patients with MEN4 have been described; all have parathyroid tumors in 
association with other tumors affecting the adrenals, pituitary and gonads (102). MEN1 is 
caused by a mutation in the tumor suppressor MEN1 gene encoding menin; MEN2 and 
MEN3 are caused by mutations in the proto-oncogene RET, encoding a tyrosine kinase 
receptor; and MEN4 is caused by mutations of CDNK1B, encoding p27 (96, 101). 
 
Hyperparathyroidism-Jaw Tumor (HPT-JT) syndrome  
The HPT-JT syndrome, an autosomal dominant disorder, is characterised by the development 
of multiple parathyroid tumors, which may be carcinomas, and fibro-osseous tumors of the 
maxilla and mandible (94). Some families also have increased risk of developing renal 
tumors and affected women have greater risk of developing uterine tumors (94). However, in 
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some families the affected individuals may have developed only parathyroid tumors without 
other tumors or jaw tumors, and this may cause confusion with other hereditary 
hypercalcemic disorders such as MEN1, FHH and FIHP (93). HPT-JT is due to mutations of 
the Cell Division Cycle 73 (CDC73) gene, which is a tumor suppressor encoding 
parafibromin that is involved in transcriptional and post-transcriptional pathways (94). 
Parathyroid tumors with hypercalcemia occur in >70% of individuals with CDC73 mutations, 
with the onset being typically in late adolescence or early adulthood (103-106). The youngest 
patient reported with hypercalcemia is 7 years old (103), and the youngest patient reported 
with parathyroid carcinoma is 20 years old (107). Germline pathogenic CDC73 mutations 
have also been reported in patients with apparently sporadic: parathyroid carcinoma; 
parathyroid adenoma; or ossifying fibromas of the jaw (108). Due to the potential for early 
onset of tumors, biochemical surveillance for PHPT, starting from age 5-10, is recommended 




Familial Hypocalciuric Hypercalcemia (FHH) 
FHH is characterized by lifelong elevations of serum calcium concentrations, elevated or 
inappropriately normal plasma PTH concentrations, and low urinary calcium excretion 
resulting from PTH–independent reduced calcium excretion in the kidneys (109). The 
hypercalcemia of FHH is considered to be primarily due to inappropriate conservation of 
calcium in the kidney rather than being driven by an inappropriate PTH concentration (109). 
The mean calcium: creatinine clearance ratio (CCCR) (measured in either molar units or 
mass units) is typically <0.01 in FHH. However, more than 20% FHH patients have a CCCR 
>0.01, and such patients are at risk of being misdiagnosed with PHPT (110-112). In contrast 
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to PHPT, the hypercalcemia in FHH is generally benign and is not corrected by 
parathyroidectomy, therefore distinguishing between PHPT and FHH is important to avoid 
unnecessary surgery in FHH patients.  
FHH is an autosomal dominant, genetically heterogeneous disorder with 3 clinically 
indistinguishable variants (FHH1-3) (111, 113). FHH1 comprises ~65% of FHH patients and 
is due to loss-of-function mutations of the calcium-sensing receptor (CaSR), a G-protein-
coupled receptor (GPCR). FHH2 comprises <5% of all FHH patients and is due to loss-of-
function mutations of GNA11, which encodes G-protein subunit α-11 (Gα11) (111). FHH3 
may occur in ~20% of FHH patients without CaSR mutations (9) and is due to loss-of-
function mutations of the adaptor-related protein complex 2, sigma 1 subunit (AP2S1) gene. 
The AP2S1 gene encodes the adaptor-protein 2 sigma (AP2σ) subunit that forms a 
heterotetramer with other subunits, and plays a central role in clathrin-mediated endocytosis 
of plasma membrane constituents such as GPCRs (9).  
As FHH is usually asymptomatic, the age of diagnosis will be variable, with 
individuals with concurrent medical problems or hypercalcemic symptoms being detected 
earlier. The youngest age of diagnosis of FHH1  is in a 4.5 month old Greek infant who had a 
urinary tract infection with incidental hypercalcemia (114). The youngest age for diagnosis of 
FHH3 is in a Japanese infant who aged 49 days presented with poor weight gain and had an 
AP2S1 mutation (115). FHH3 children are more likely than FHH1 children to be 
symptomatic, and to have additional phenotypic features, and thus may present earlier (116). 
For example, four FHH3 children, aged <1 to 11 years, have been reported to have learning 
difficulties (LD); one aged 14 years had LD, pancreatitis and short stature (SS); and one aged 
15 years had LD, an atrial septal defect, and SS (116).  
Neonatal Severe Primary Hyperparathyroidism (NSHPT) 
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Neonatal severe primary hyperparathyroidism (NSHPT) usually presents at birth with marked 
hypercalcemia, hypotonia, respiratory distress and bone demineralisation, and is usually fatal 
by 3 months if untreated. Bone demineralization occurs due to osteoclast over-activity and 
can result in bone deformities and fractures presenting at birth. Respiratory difficulties may 
arise from rib cage involvement. Most cases are associated with homozygous or compound 
heterozygous loss-of-function CaSR mutations (117) and some may occur in FHH families, 
either through inheriting two mutated copies of the CASR gene as in consanguineous 
families, or one copy together with a de novo CASR mutation. Urgent parathyroidectomy is 
life saving and the treatment of choice, but pamidronate or cinacalcet have been used for 
treatment whilst awaiting surgery (118). Cinacalcet is a positive allosteric modulator of the 
CaSR and will ameliorate signalling disturbances associated with most loss-of-function CaSR 
mutations; however if both CASR alleles have mutations whereby the CaSR is not expressed 
e.g. with a homozygous deletion in exon 5 (c.1392_1404del13), then cinacalcet will be 
ineffective (119). Some centres distinguish between NSHPT and neonatal 
hyperparathyroidism (NHPT) on the basis of homozygous and heterozygous CaSR mutations, 
respectively. NHPT may be associated with less marked and symptomatically transient 
hypercalcemia than NSHPT, with some patients developing symptom-less FHH, and 
therefore not requiring parathyroid surgery (120). This highlights the value of CASR 
mutational analysis in distinguishing NSHPT from NHPT.  
Familial Isolated Primary Hyperparathyroidism (FIHP) 
FIHP is characterized by hereditary PHPT occurring without the association of other tumors 
and has been described in >100 families (91, 93). The diagnosis of FIHP is based on 
excluding other hereditary disorders associated with PHPT such as MEN1, MEN2, MEN4, 
HPT-JT and FHH, and by screening for mutations in known causative genes, such as MEN1, 
RET, CDKN1B, CDC73, and CASR respectively (91). In the majority of these families the 
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genetic etiology of FIHP remains unknown (121, 122). However patients with activating 
mutations of glial cells missing 2 (GCM2), a parathyroid-specific transcription factor, have 
been reported (123), as well as one PHPT patient who had a nonsense mutation of the PTH 
gene (124). Approximately 10% of patients presenting under the age of 45 years with 
sporadic PHPT will have a de novo germline MEN1, CDC73, GCM2 or CASR mutation (93-
95, 125, 126), and this has implications for their future management, to ensure appropriate 
screening for complications associated with the specific syndrome, and for screening first-
degree relatives. The finding of a mutation in MEN1, RET, CDC73 or CDKN1B in an 
apparent FIHP kindred would lead to a revised diagnosis of one of the associated syndromes 
with incomplete penetrance (93) and, in some families, FIHP may represent an incomplete 
manifestation of a syndromic form of PHPT caused by an as yet undiscovered mutation (93, 
127, 128). Some patients diagnosed as having FIHP have later been reported to develop 
features of MEN1 (93-97, 127) and, in addition, some FIHP kindreds have associated MEN1 
mutations and may represent an allelic variant of MEN1 (127).  
FIHP may be distinguished from MEN1, FHH and HPT-JT through clinical, 
histological and genetic findings. Over 90% of MEN1 and HPT-JT patients develop 
hypercalcemia as their first manifestation of the disease, and distinguishing between MEN1 
and HPT-JT patients at this early stage from FIHP patients can be difficult (91, 93, 98). It is 
important to distinguish FIHP from HPT-JT, as HPT-JT patients are at higher risk for 
developing parathyroid carcinomas (129-132). The presence of ossifying fibromas of the jaw 
is an important distinguishing feature of HPT-JT and the identification of renal, pancreatic, 
thyroid, and testicular abnormalities may also help to identify HPT-JT patients. The jaw 
tumors in HPT-JT differ from the brown tumors observed in some PHPT patients and do not 
resolve after parathyroidectomy (133). Similarly, the occurrence of pancreatic, pituitary or 
adrenal tumors in the patient or family will suggest a diagnosis of MEN1 rather than FIHP. 
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FIHP may be distinguished from FHH on the basis of plasma and urinary calcium findings. 
In FHH, serum calcium levels are elevated from the neonatal period, whereas in FIHP, 
hypercalcemia rarely occurs until after the first decade (98, 127). FIHP patients are likely to 
have associated hypercalciuria, unlike FHH patients who usually have a CCCR <0.01 (116). 
However, there are considerable clinical overlaps between these disorders, and genetic testing 
is advisable for making the correct diagnosis. 
 
Genetic testing in patients with syndromic and non-syndromic forms of PHPT 
Genetic testing for mutations in PHPT patients is worthwhile as >10% of patients with PHPT 
will have a mutation in one of 13 genes (Table 3) and therefore benefit from an accurate 
diagnosis (91). Thus, genetic testing may provide confirmation of the clinical diagnosis (i.e. 
syndromic or non-syndromic PHPT) and allow appropriate screening for associated tumors to 
be undertaken, with implementation of appropriate treatment, e.g: early parathyroidectomy 
for HPT-JT patients who are at increased risk of developing parathyroid carcinomas; 
appropriate parathyroid surgery in MEN1 patients who generally have multigland disease 
requiring open neck exploration; and avoidance of unnecessary parathyroidectomies in FHH 
patients (91). Asymptomatic mutation carriers should receive screening for associated tumors 
to facilitate appropriate treatment, and the 50% of family members who do not harbor the 
germline mutation can be reassured and alleviated of the anxiety of developing the condition 
(93-95), thereby reducing costs to the individuals, and also to the health services in avoiding 
unnecessary biochemical and radiological investigations (93-95, 98).   
Indications for genetic testing in PHPT patients include: 1) young age of presentation, 
i.e. <45 years of age; 2) multigland disease; 3) parathyroid carcinoma or atypical parathyroid 
adenomas (e.g. with fibrous bands or cysts); 4) being a first-degree relative of a known 
mutation carrier; and 5) being an index case with 2 or more MEN syndrome associated
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tumors (93-95, 98, 126, 134). Patients should be offered genetic counselling prior to testing, 
and genetic testing should use non-tumor cells, (e.g. DNA obtained from leukocytes, salivary 
cells, skin cells or hair follicles), as DNA from parathyroid tumors may contain multiple 
mutations in addition to the germline mutation and therefore is not clinically useful (91). 
Individuals with PHPT identified to have a germline mutation should enter into an 
appropriate screening programme, e.g. for MEN and HPT-JT associated tumors (93, 94). If 
no genetic abnormalities are found within the 13 genes (Table 3), and clinical manifestations 
of hereditary or syndromic forms of PHPT are absent, then the likelihood of a MEN 
syndrome, HPT-JT or FHH is low (i.e. <5%) (93-95, 98). The first-degree relatives of PHPT 
patients, including children, with a germline mutation should be offered genetic counselling 
and appropriate gene testing, and any affected individuals subsequently identified should also 
enter into an appropriate screening programme, even if asymptomatic (93-95, 134). First-
degree relatives who have not inherited the causative mutation require no further follow-up 
and can be reassured (93, 94).  
Patients who present with PHPT at a later age, i.e. >45 years, and who have an 
underlying syndromic etiology for their PHPT, are more likely to have manifested other 
associated features that may be revealed during clinical evaluation. A detailed family history 
for PHPT (i.e. FIHP), MEN syndrome, HPT-JT or FHH should be undertaken, and gene 
testing should then be offered to determine the etiology of the PHPT (93-95, 110, 124, 134). 
However, up to 5% of patients >45 years of age with sporadic PHPT due to a solitary 
parathyroid adenoma may have a germline mutation involving CDKN1A, CDKN2, or 
CDKN2C (91), and this may have implications for their children. Such first-degree relatives 
of a patient with a mutation in CDKN1A, CDKN1B or CDKN1C who are also found to be 
mutation carriers should then have periodic screening to detect the onset of hypercalcemia in 
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order to facilitate appropriate earlier treatment aimed at preventing the skeletal and renal 
complications of PHPT (93, 95, 97, 98). 
 
ACQUIRED CAUSES OF NEONATAL HYPERCALCEMIA 
 
Neonatal hyperparathyroidism 
Neonatal hyperparathyroidism may be an adaptation to maternal hypocalcemia due to 
hypoparathyroidism, vitamin D deficiency, pseudohypoparathyroidism or renal tubular 
acidosis (4), although in the latter, PTH is often high with normal calcium. Maternal 
hypervitaminosis D does not usually affect the neonate, as 1,25(OH)2D3  is inactivated by the 
placenta, so excessive maternal 1,25(OH)2D3 consumption should not cause hypercalcemia in 
the newborn. However, there have been case reports of excessive maternal intake of 
1,25(OH)2D3 and 25(OH)D3 causing hypercalcemia in the neonate (135, 136). 
 
Extracorporeal membrane oxygenation 
Extracorporeal membrane oxygenation (ECMO) is a technique used in pediatric resuscitation 
as a way of providing tissue oxygenation in cases of refractory hypoxemia to allow time for 
treatment of the underlying cause of the disorder to take effect. It is associated with metabolic 
disturbances including hypercalcemia (137-139), although the mechanisms for this are not 
known, but may be related to increased circulating PTH concentrations (138).  
 
MANAGEMENT OF HYPERCALCEMIA 
The management of hypercalcemia involves establishing the underlying diagnosis in parallel 
with lowering serum calcium levels. Medications, which may cause or exacerbate the 
hypercalcemia, such as calcium and vitamin D preparations should be stopped. Symptomatic 
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hypercalcemia may require fluid administration to rectify intravascular volume contraction 
caused by hypercalcemia-induced nephrogenic diabetes insipidus (140). Normal (0.9%) 
saline given intravenously is effective at rehydrating the patient, thereby diluting serum 
calcium concentrations (5). Moreover, normal saline lowers serum calcium concentrations by 
promoting urinary calcium excretion from the proximal renal tubule and Loop of Henle 
(140). Loop diuretics such as furosemide can also enhance urinary calcium excretion (140), 
but should be used cautiously, as they may exacerbate the intravascular volume contraction 
and lead to renal impairment (4). Subcutaneous calcitonin is an effective anti-resorptive agent 
for symptomatic hypercalcemia, however its effects are short-lived due to tachyphylaxis  (4). 
The use of I-V bisphosphonates leads to a more sustained reduction in serum calcium 
concentrations, and pamidronate (0.5-1.0 mg/kg) is used most commonly in children (140). 
Patients should be adequately hydrated prior to receiving I-V bisphosphonates in order to 
minimise the potential risk of nephrotoxicity, which has been widely reported in adults (141). 
Glucocorticoids such as prednisolone are effective at rectifying hypercalcemia caused by 
granulomatous disorders, although long-term use may increase skeletal fragility and impair 
linear growth (4) (140). Cinacalcet, which is a CaSR positive allosteric modulator, has been 
successfully used to manage life-threatening hypercalcemia in some NSHPT probands (142). 
However, the effectiveness of cinacalcet for NSHPT will depend on the underlying CaSR 
mutation, and patients harboring biallelic truncating CaSR mutations will be unlikely to 
respond to this calcimimetic agent (143). Parathyroidectomy remains the treatment of choice 
for children with primary hyperparathyroidism or NSHPT, as it represents a curative 
procedure for these disorders (144). Hypocalcemia due to hungry bone syndrome or 
postsurgical hypoparathyroidism represents the most common complication of 
parathyroidectomy, and close monitoring of serum calcium concentrations is required 





The majority of causes of hypercalcemia in children are similar to those in adults, but occur 
at different frequencies across the age spectrum from birth to maturity. Hypercalcemia has a 
broad differential diagnosis (Table 1), and comprehensive clinical assessment followed by 
step-wise use of investigations is necessary to elucidate the underlying cause (Figure 2). 
Determining the etiology of hypercalcemia is critical for successful treatment, and for 
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Table 1. Causes of hypercalcemia in children 
 PTH-dependent hypercalcemia PTH-independent hypercalcemia 




• MEN 1,2, 3 and 4 
• HPT-JT  
• IIH 
• Williams syndrome 
• Down syndrome 
• Hypophosphatasia 
• Jansen’s disease 
• Inborn errors of metabolism, e.g. CLD, 
Bartter syndrome, blue diaper syndrome, 
sucrose-isomaltase	deficiency, primary 
oxalosis, IMAGe syndrome 
 
Acquired • Tertiary hyperparathyroidism due to 
chronic renal failure or treatment for 
hypophosphatemic rickets 
• Gestational maternal hypocalcemia 
• Hypervitaminosis D and A 
• Malignancies causing osteolysis (e.g. ALL, 
AML), or secreting PTHrP (e.g. lymphoma, 
medulloblastoma, rhabdomyosarcoma, 
hepatoblastoma or hepatocellular 
carcinoma), or secreting 1,25(OH)2D3 (e.g. 
lymphoma or ovarian dysgerminoma) 
• Drugs, e.g. thiazides, chemotherapy 
including 13-cis-retinoic acid, milk-alkali 
syndrome 
• Granulomatous disease, e.g. subcutaneous 
fat necrosis of the newborn, tuberculosis, 
sarcoidosis, HIV immune reconstitution 
syndrome, cat scratch fever, histoplasmosis, 
coccidiomycosis, leprosy 
• Endocrinopathies, e.g. thyrotoxicosis, 
congenital hypothyroidism, Addison’s 
disease, pheochromocytoma 
• Distal renal tubular acidosis 
•  Multicystic dysplastic kidney disease and 
renal dysplasia 
• Chronic inflammatory disorders, e.g. Crohn’s 
disease 
• Infection, e.g. disseminated CMV 
• Immobilisation 
































8.2-11.2	 2.05-2.80	 5.20-6.40b	 1.30-1.60b	
Neonate	(24h)	
	
NR	 NR	 4.40-5.44b	 1.10-1.36b	
Neonate	(5d)	
	
NR	 NR	 4.88-5.92b	 1.22-1.38b	
Birth	to	90d	
	
8.0-11.3a	 2.00-2.80a	 NR	 NR	
91-180d	
	
8.9-11.2a	 2.20-2.80a	 NR	 NR	
181-364d	
	
9.0-11.3a	 2.30-2.80a	 NR	 NR	
1-3y	
	
8.9-11.1a	 2.20-2.80a	 4.80-5.52b	 1.20-1.38b	
4-11y	
	
8.7-10.7a	 2.20-2.70a	 4.80-5.52b	 1.20-1.38b	
12-18y	
	
8.5-10.7a	 2.10-2.70a	 4.80-5.52b	 1.20-1.38b	
>19y	
	







































Figure 1. Hormonal regulation of extracellular calcium homeostasis. Parathyroid hormone (PTH) is the principle 
calcitropic hormone, and acts to elevate calcium levels by promoting osteoclastic activity on bone, increasing 
reabsorption of calcium from renal distal tubules and collecting ducts, and stimulating renal enzyme 1alpha-
hydroxylase (1α-hydroxylase) conversion of 25-hydroxyvitamin D3 (25(OH)D3) into the active 1,25-
hydroxyvitamin D3 (1,25(OH)2D3). 25(OH)D3 is produced from vitamin D3, formed by the action of solar UV-B on 
the skin or taken in through the diet,  by the liver enzyme 25-hydroxylase. 1,25(OH)2D3 is released into the circu-
lation and stimulates calcium uptake from the gut. Rising serum calcium levels are detected by the calcium-
sensing receptor (CaSR), which facilitates a negative feedback on the parathyroid glands and PTH secretion 
attenuates to maintain homeostasis. 1,25(OH)2D3 is also regulated by Fibroblast Growth Factor-23 (FGF-23), the 
main function of which is to regulate plasma phosphate concentrations. It is secreted by osteocytes in response 
to an elevated 1,25(OH)2D3 concentration and acts on the kidney proximal tubules to inhibit reabsorption and 
increase excretion of phosphate. It also inhibits 1α-hydroxylase, thereby exerting a negative feedback on 
1,25(OH)2D3 and promotes the action of 1,25(OH)2D3 24-hydroxylase, leading to lower levels of 1,25(OH)2D3 and 
reduced calcium absorption from the gut.
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Figure 2. Clinical approach to inves!ga!on of causes of hypercalcemia in a child
aConfirm hypercalcemia, defined as plasma (or serum) adjusted calcium >10.5mg/dL (2.60mmol/L) or ionized 
calcium >5.25mg/dL (1.32 mmol/L) (see Table 2)
bPTH – parathyroid hormone
c25(OH)2D – 25-hydroxyvitamin D
dFHH1-3 – Familial Hypocalcaiuric Hypercalcemia types 1-3; MEN1 – Mul!ple Endocrine Neoplasia type 1; 
MEN2 – Mul!ple Endocrine Neoplasia type 2; MEN3 – Mul!ple Endocrine Neoplasia type 3; MEN4 – Mul!ple 
Endocrine Neoplasia type 4; NSHPT – Neonatal Severe Hyperparathyroidism; HPT-JT – Hyperparathyroid-Jaw 
Tumour syndrome
eFamilial Isolated Hyperparathyroidism
fCondi!ons aﬀec!ng neonates (shown in italics)
g1,25(OH)2D – 1,25-dihydroxyvitamin D
hInborn errors of metabolism, e.g. Hypophosphatasiai, Congenital Lactase Deficiency (CLD) and blue diaper 
syndrome





• Vitamin D intoxication 
• Enriched formula
Consider: 
• Idiopathic Infantile Hypercalcemia
• Granulomatous diseases
• Malignancy
• Subcutaneous fat necrosis of the
Consider: 
• Drugs - vitamin A intoxication, thiazides
chemotherapy 
• Endocrinopathies - hyperthyroidism, Addison’s 
disease, pheochromocytoma, severe 
congenital hypothyroidismf
• Inborn errors of metabolismhi
• Immobilisation
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